In this scholarly study, we assessed the cost-effectiveness of VDZ weighed against other branded biologics (ADA, GOL, and IFX) for the treating sufferers with moderate-to-severe active UC who’ve not sufficiently taken care of immediately CT from japan open public healthcare payer perspective
In this scholarly study, we assessed the cost-effectiveness of VDZ weighed against other branded biologics (ADA, GOL, and IFX) for the treating sufferers with moderate-to-severe active UC who’ve not sufficiently taken care of immediately CT from japan open public healthcare payer perspective. Methods Model Structure An economic super model tiffany livingston using a cross types…